NTX-471 / Nutcracker Therap - LARVOL DELTA

Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting (Businesswire) - "Nutcracker Therapeutics, Inc...presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250...Key highlights of the data include...Administering mice with formulated mRNA molecules encoding the tetravalent, octavalent, and bispecific SIRPa fully eradicated established subcutaneous tumors, and resulted in robust protein expression (~10-100ug/ml) with high purity/homogeneity similar to, or better than, DNA-expressed proteins...Two doses of mNTX-250 treatment eradicated well-established HPV16-transformed tumors, and improved overall survival in mice. The treated animals also generated significant numbers of HPV-16 E7 antigen-specific T cells....Mice treated with NTX-010 generated fewer HPV16 antigen-specific T cells. When rechallenged, 6 out of 11 NTX-010-treated mice showed tumor growth."

Preclinical • Oncology • Solid Tumor

NTX-0471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA expressed in-vivo biologics (SITC 2023) - "Conclusions We demonstrate that significant enhancement in therapeutic window and efficacy could be achieved by engineering complex multivalent and bispecific molecules. Further, systemic delivery of mRNA encoding these complex molecules avoids the need to produce and retain stability using the traditional cell line development paradigm which is often challenging."

IO biomarker • Preclinical • Oncology • CCR4 • CD47 • SIRPA

Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023 (Businesswire) - "Nutcracker Therapeutics, Inc...announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4....Nutcracker’s presentation on NTX-250 will describe how its three RNA-encoded protein components (HPV E6/E7, IL-12, and LIGHT) work together to drive enhanced immune responses and tumor clearance in murine models of HPV-driven tumors, while also providing immunogenic memory. The presentation on NTX-471 will describe unique mRNA compositions that can selectively target CD47 on cancerous cells over those on red blood cells, potentially alleviating the anemic side effects seen with anti-CD47 drugs currently under development."

Preclinical • Oncology • Solid Tumor